Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study-Reference-Cited by-同舟云学术

Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study

Published:2023-06 Issue:6 Volume:24 Page:624-635
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jenei Kristina,Raymakers Adam J N,Bayle Arnaud,Berger-Thürmel Karin,Cherla Avi,Honda Kazunori,Jackson Christopher C G A,Karikios Deme,Trapani Dario,Berry Scott,Gyawali Bishal

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Economic burden of malignant blood disorders across Europe: a population-based cost analysis;Burns;Lancet Haematol,2016

2. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis;Vokinger;Lancet Oncol,2020

3. Comparison of cancer-related spending and mortality rates in the US vs 21 high-income countries;Chow;JAMA Health Forum,2022

4. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring;Gyawali;ESMO Open,2021

5. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks;Del Paggio;Lancet Oncol,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022);Annals of Internal Medicine;2024-09-03

2. A review of 25 years of National Institute of Health and Care Excellence decision making;Journal of Comparative Effectiveness Research;2024-09

3. Pharmaceutical company funding of cancer patient advocacy organizations in the Netherlands;Journal of Cancer Policy;2024-09

4. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis;The Lancet Oncology;2024-08

5. Factors influencing the reimbursement of cancer drugs in Europe: A scoping review;Journal of Evaluation in Clinical Practice;2024-07-03